Patients with coronary artery disease who underwent PCI
Conditions
Interventions
Pitavastatin 2~4mg daily
Atorvastatin 10~20mg daily
Sponsors
Kawasaki Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with hypercholesterolemia who satisfied each criteria below -LDL-C level is equal or greater than 100 mg/dL -requiring cholesterol lowering drugs judged by attending physicians 2.Patients given written informed consent
Exclusion criteria
Exclusion criteria: 1.Patients who met contraindication of LIVALO tablet below - Patients who have hypersensitivity to LIVALO tablet -Patients who have severe liver dysfunction or biliary atresia. -Co-administration with cyclosporine -Women who are pregnant or may become pregnant or nursing mothers 2.Patients who meet contraindication of LIPITOL tablet below - Patients who have hypersensitivity to LIPITOL tablet -Patients with the following diseases considered to be associated with defective hepatic metabolism: acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, hepatic carcinoma and/or icterus -Women who are pregnant or may become pregnant or nursing mothers 3.Patients with hepatic disorders (ALT or AST level is equal or greater than 100IU/L) 4.Patients who are ineligible in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite cardiovascular events Occurrence of one of following events 1.Cardiovascular death 2.Non-fatal Myocardial Infarction (MI) 3.Non-fatal Cerebral Infarction (CI) 4.Repeated revascularization including bypass surgery, target lesion revascularization and repeated PCI for de novo lesion | — |
Countries
Japan
Contacts
Public ContactTakao Maruyama
Kawasaki Hospital Department of Cardiology
Outcome results
None listed